| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinocerebellar Ataxias | 104 | 2025 | 254 | 18.510 |
Why?
|
| Myotonic Dystrophy | 46 | 2023 | 149 | 4.840 |
Why?
|
| Machado-Joseph Disease | 22 | 2025 | 26 | 4.630 |
Why?
|
| Ataxin-10 | 25 | 2025 | 28 | 4.030 |
Why?
|
| Microsatellite Repeats | 21 | 2022 | 236 | 3.960 |
Why?
|
| Trinucleotide Repeat Expansion | 38 | 2025 | 128 | 3.850 |
Why?
|
| Cerebellar Ataxia | 12 | 2025 | 69 | 3.260 |
Why?
|
| DNA Repeat Expansion | 35 | 2025 | 79 | 3.230 |
Why?
|
| Nerve Tissue Proteins | 34 | 2024 | 1132 | 2.600 |
Why?
|
| Ataxia | 12 | 2023 | 177 | 2.030 |
Why?
|
| RNA | 10 | 2023 | 549 | 1.690 |
Why?
|
| Spinocerebellar Degenerations | 9 | 2024 | 64 | 1.510 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 19 | 2010 | 357 | 1.480 |
Why?
|
| Friedreich Ataxia | 18 | 2024 | 48 | 1.470 |
Why?
|
| Epilepsy | 13 | 2025 | 891 | 1.370 |
Why?
|
| Trinucleotide Repeats | 23 | 2017 | 109 | 1.260 |
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2020 | 228 | 1.230 |
Why?
|
| Humans | 270 | 2025 | 132105 | 1.190 |
Why?
|
| Cerebellum | 12 | 2025 | 463 | 1.180 |
Why?
|
| Mutation | 40 | 2020 | 6249 | 1.150 |
Why?
|
| Huntington Disease | 16 | 2014 | 144 | 1.130 |
Why?
|
| Haplotypes | 13 | 2024 | 545 | 1.130 |
Why?
|
| Neural Stem Cells | 5 | 2018 | 151 | 1.030 |
Why?
|
| Phenotype | 36 | 2021 | 4541 | 1.000 |
Why?
|
| Adult | 119 | 2025 | 31557 | 0.990 |
Why?
|
| Genetic Testing | 13 | 2019 | 1098 | 0.920 |
Why?
|
| Gene Frequency | 8 | 2024 | 751 | 0.920 |
Why?
|
| Middle Aged | 106 | 2025 | 28936 | 0.910 |
Why?
|
| Purkinje Cells | 2 | 2019 | 165 | 0.890 |
Why?
|
| Disease Progression | 18 | 2025 | 2227 | 0.890 |
Why?
|
| Ataxin-3 | 9 | 2021 | 10 | 0.880 |
Why?
|
| White Matter | 3 | 2025 | 211 | 0.870 |
Why?
|
| Male | 149 | 2025 | 64918 | 0.850 |
Why?
|
| Nerve Degeneration | 3 | 2014 | 129 | 0.830 |
Why?
|
| Alleles | 30 | 2024 | 1684 | 0.820 |
Why?
|
| Neuromuscular Diseases | 4 | 2017 | 50 | 0.810 |
Why?
|
| Genotype | 21 | 2020 | 2706 | 0.810 |
Why?
|
| Age of Onset | 34 | 2025 | 626 | 0.800 |
Why?
|
| Pedigree | 36 | 2021 | 1725 | 0.780 |
Why?
|
| Polymorphism, Genetic | 13 | 2013 | 803 | 0.780 |
Why?
|
| Peptides | 8 | 2025 | 846 | 0.770 |
Why?
|
| DNA | 19 | 2011 | 1483 | 0.750 |
Why?
|
| DNA, Catalytic | 1 | 2021 | 4 | 0.720 |
Why?
|
| Brazil | 15 | 2025 | 138 | 0.710 |
Why?
|
| Female | 131 | 2025 | 70680 | 0.700 |
Why?
|
| Fibroblasts | 6 | 2019 | 877 | 0.700 |
Why?
|
| Repressor Proteins | 9 | 2020 | 815 | 0.700 |
Why?
|
| Tremor | 6 | 2022 | 136 | 0.650 |
Why?
|
| Parkinson Disease | 9 | 2019 | 739 | 0.640 |
Why?
|
| Communication Disorders | 2 | 2017 | 10 | 0.630 |
Why?
|
| Myelin Sheath | 1 | 2020 | 125 | 0.620 |
Why?
|
| Indians, South American | 4 | 2015 | 14 | 0.620 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 7 | 2020 | 79 | 0.610 |
Why?
|
| Genome, Human | 5 | 2015 | 1332 | 0.600 |
Why?
|
| Oligonucleotides | 2 | 2019 | 95 | 0.600 |
Why?
|
| Nervous System Diseases | 3 | 2017 | 411 | 0.580 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 311 | 0.580 |
Why?
|
| Myasthenia Gravis | 11 | 2000 | 69 | 0.570 |
Why?
|
| Liposomes | 1 | 2019 | 203 | 0.560 |
Why?
|
| Severity of Illness Index | 20 | 2025 | 3083 | 0.550 |
Why?
|
| DNA Repair Enzymes | 4 | 2020 | 43 | 0.540 |
Why?
|
| Emotions | 2 | 2017 | 367 | 0.530 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 30 | 0.530 |
Why?
|
| Base Sequence | 21 | 2017 | 2902 | 0.530 |
Why?
|
| Polymerase Chain Reaction | 23 | 2015 | 1554 | 0.520 |
Why?
|
| Metalloendopeptidases | 1 | 2017 | 100 | 0.520 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 131 | 0.510 |
Why?
|
| DNA Mutational Analysis | 13 | 2019 | 825 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2851 | 0.480 |
Why?
|
| Aged | 61 | 2025 | 21413 | 0.470 |
Why?
|
| Cerebellar Diseases | 4 | 2025 | 81 | 0.470 |
Why?
|
| Receptors, Cholinergic | 11 | 2002 | 77 | 0.470 |
Why?
|
| Motor Neurons | 3 | 2012 | 134 | 0.460 |
Why?
|
| Gait | 3 | 2020 | 140 | 0.460 |
Why?
|
| Myotonic Disorders | 2 | 2013 | 2 | 0.460 |
Why?
|
| Myotonin-Protein Kinase | 13 | 2023 | 45 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 22 | 5 | 2003 | 102 | 0.450 |
Why?
|
| Molecular Sequence Data | 29 | 2015 | 3778 | 0.440 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 79 | 0.440 |
Why?
|
| Indians, Central American | 1 | 2013 | 3 | 0.430 |
Why?
|
| Lymphocytes | 7 | 2018 | 365 | 0.420 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1975 | 0.420 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 258 | 0.420 |
Why?
|
| Genes, Dominant | 7 | 2013 | 251 | 0.400 |
Why?
|
| Dermis | 1 | 2013 | 27 | 0.400 |
Why?
|
| Brain | 11 | 2020 | 3201 | 0.400 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 1285 | 0.400 |
Why?
|
| Chromosome Mapping | 11 | 2015 | 1097 | 0.390 |
Why?
|
| Myotonia Congenita | 4 | 2008 | 5 | 0.390 |
Why?
|
| Cell Line | 12 | 2020 | 2730 | 0.380 |
Why?
|
| Eye Movements | 1 | 2012 | 79 | 0.370 |
Why?
|
| Chloride Channels | 4 | 2008 | 63 | 0.370 |
Why?
|
| RNA-Binding Proteins | 6 | 2018 | 605 | 0.360 |
Why?
|
| Mexico | 11 | 2025 | 185 | 0.360 |
Why?
|
| Introns | 6 | 2021 | 304 | 0.350 |
Why?
|
| Animals | 46 | 2024 | 34953 | 0.350 |
Why?
|
| Seizures | 3 | 2025 | 895 | 0.350 |
Why?
|
| Neurogenesis | 1 | 2012 | 221 | 0.340 |
Why?
|
| Motor Activity | 3 | 2016 | 521 | 0.340 |
Why?
|
| Point Mutation | 4 | 2012 | 350 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2025 | 3854 | 0.330 |
Why?
|
| Neurology | 2 | 2003 | 118 | 0.320 |
Why?
|
| Migraine Disorders | 2 | 2010 | 65 | 0.310 |
Why?
|
| Shaw Potassium Channels | 3 | 2013 | 8 | 0.310 |
Why?
|
| Dystonia | 3 | 2017 | 173 | 0.310 |
Why?
|
| Cohort Studies | 14 | 2025 | 5150 | 0.310 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 189 | 0.300 |
Why?
|
| Alternative Splicing | 4 | 2020 | 363 | 0.300 |
Why?
|
| Genes, Recessive | 4 | 2013 | 195 | 0.290 |
Why?
|
| Genetic Therapy | 4 | 2024 | 720 | 0.290 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2013 | 179 | 0.290 |
Why?
|
| Young Adult | 17 | 2025 | 9940 | 0.280 |
Why?
|
| Ataxin-2 | 3 | 2020 | 10 | 0.280 |
Why?
|
| Gene Expression | 6 | 2017 | 1564 | 0.280 |
Why?
|
| Suicidal Ideation | 2 | 2025 | 254 | 0.280 |
Why?
|
| Neoplasms | 2 | 2020 | 2953 | 0.280 |
Why?
|
| Protein Kinases | 4 | 1997 | 331 | 0.280 |
Why?
|
| Receptors, Nicotinic | 5 | 1994 | 133 | 0.280 |
Why?
|
| Carrier Proteins | 2 | 2011 | 1050 | 0.280 |
Why?
|
| Tourette Syndrome | 2 | 2003 | 158 | 0.280 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 281 | 0.280 |
Why?
|
| Basal Ganglia Diseases | 1 | 2007 | 26 | 0.270 |
Why?
|
| Mitosis | 2 | 2015 | 201 | 0.270 |
Why?
|
| Iron-Binding Proteins | 8 | 2012 | 33 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 3358 | 0.270 |
Why?
|
| Cells, Cultured | 10 | 2017 | 3061 | 0.260 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 7119 | 0.260 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2006 | 33 | 0.250 |
Why?
|
| Depression | 5 | 2024 | 1351 | 0.250 |
Why?
|
| Neurites | 1 | 2006 | 45 | 0.250 |
Why?
|
| Depressive Disorder | 1 | 2010 | 481 | 0.250 |
Why?
|
| Olfaction Disorders | 2 | 2019 | 30 | 0.240 |
Why?
|
| Ataxins | 3 | 2017 | 114 | 0.240 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2005 | 22 | 0.240 |
Why?
|
| Genetic Linkage | 10 | 2013 | 475 | 0.240 |
Why?
|
| Peptide Fragments | 9 | 2019 | 799 | 0.230 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 1495 | 0.230 |
Why?
|
| Pyramidal Tracts | 2 | 2020 | 37 | 0.230 |
Why?
|
| Genetic Counseling | 4 | 2002 | 246 | 0.230 |
Why?
|
| Genetic Variation | 5 | 2017 | 1581 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2023 | 6530 | 0.230 |
Why?
|
| Muscles | 10 | 2020 | 239 | 0.230 |
Why?
|
| Fatigue | 2 | 2024 | 198 | 0.230 |
Why?
|
| Mice | 21 | 2021 | 18566 | 0.230 |
Why?
|
| Family Health | 8 | 2013 | 256 | 0.220 |
Why?
|
| Biomarkers | 6 | 2025 | 3380 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 154 | 0.220 |
Why?
|
| DNA, Mitochondrial | 3 | 2010 | 243 | 0.210 |
Why?
|
| Isoenzymes | 3 | 2001 | 222 | 0.210 |
Why?
|
| Adolescent | 32 | 2025 | 20532 | 0.210 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 428 | 0.210 |
Why?
|
| Comorbidity | 5 | 2020 | 1606 | 0.210 |
Why?
|
| Quality of Life | 3 | 2024 | 2152 | 0.210 |
Why?
|
| Mexican Americans | 2 | 2002 | 168 | 0.210 |
Why?
|
| Essential Tremor | 3 | 2004 | 94 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 313 | 0.200 |
Why?
|
| Peru | 2 | 2021 | 56 | 0.200 |
Why?
|
| Spermatozoa | 4 | 2004 | 243 | 0.200 |
Why?
|
| Case-Control Studies | 10 | 2020 | 3418 | 0.200 |
Why?
|
| HEK293 Cells | 3 | 2021 | 796 | 0.200 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 248 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 211 | 0.200 |
Why?
|
| Chorea | 4 | 2004 | 39 | 0.190 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2023 | 79 | 0.190 |
Why?
|
| Founder Effect | 2 | 2020 | 35 | 0.190 |
Why?
|
| Gene Silencing | 2 | 2021 | 240 | 0.190 |
Why?
|
| Transcription, Genetic | 5 | 2019 | 1425 | 0.190 |
Why?
|
| Amino Acid Sequence | 15 | 2011 | 2674 | 0.190 |
Why?
|
| Membrane Glycoproteins | 2 | 2023 | 421 | 0.180 |
Why?
|
| Ubiquinone | 2 | 2014 | 29 | 0.180 |
Why?
|
| RNA, Messenger | 7 | 2023 | 2679 | 0.180 |
Why?
|
| Kearns-Sayre Syndrome | 1 | 2001 | 5 | 0.180 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 201 | 0.180 |
Why?
|
| Nucleic Acid Conformation | 2 | 2017 | 182 | 0.170 |
Why?
|
| Huntingtin Protein | 2 | 2019 | 64 | 0.170 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2021 | 25 | 0.170 |
Why?
|
| Mice, Inbred ICR | 2 | 2019 | 152 | 0.170 |
Why?
|
| Autoantibodies | 5 | 2000 | 458 | 0.170 |
Why?
|
| Stereotaxic Techniques | 1 | 2021 | 79 | 0.170 |
Why?
|
| Genetic Techniques | 2 | 2001 | 104 | 0.170 |
Why?
|
| Replication Protein C | 1 | 2020 | 7 | 0.170 |
Why?
|
| Transfection | 3 | 2018 | 999 | 0.170 |
Why?
|
| Mutant Proteins | 2 | 2019 | 117 | 0.170 |
Why?
|
| Genomic Instability | 3 | 2013 | 248 | 0.170 |
Why?
|
| Multiple System Atrophy | 1 | 2020 | 18 | 0.170 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 550 | 0.170 |
Why?
|
| Fragile X Syndrome | 1 | 2022 | 155 | 0.170 |
Why?
|
| 3' Untranslated Regions | 3 | 2018 | 160 | 0.170 |
Why?
|
| Electrophoresis, Capillary | 1 | 2020 | 13 | 0.160 |
Why?
|
| DNA Repair | 3 | 2019 | 567 | 0.160 |
Why?
|
| C9orf72 Protein | 2 | 2017 | 51 | 0.160 |
Why?
|
| DNA End-Joining Repair | 1 | 2020 | 38 | 0.160 |
Why?
|
| Mitomycin | 4 | 2015 | 53 | 0.160 |
Why?
|
| Rett Syndrome | 1 | 2003 | 290 | 0.160 |
Why?
|
| RNA Polymerase II | 1 | 2020 | 87 | 0.160 |
Why?
|
| Muscular Dystrophies | 3 | 2013 | 54 | 0.160 |
Why?
|
| Postural Balance | 1 | 2020 | 131 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 3738 | 0.150 |
Why?
|
| Codon, Terminator | 2 | 2012 | 27 | 0.150 |
Why?
|
| RNA Splicing | 3 | 2018 | 243 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2000 | 182 | 0.150 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 2453 | 0.150 |
Why?
|
| Genetic Markers | 7 | 2020 | 619 | 0.150 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2018 | 8 | 0.150 |
Why?
|
| Anticipation, Genetic | 4 | 2013 | 5 | 0.150 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 1997 | 0.150 |
Why?
|
| Brain Diseases | 2 | 1998 | 307 | 0.150 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 259 | 0.150 |
Why?
|
| Scoliosis | 1 | 2020 | 143 | 0.150 |
Why?
|
| Microvessels | 1 | 2019 | 66 | 0.150 |
Why?
|
| Minisatellite Repeats | 2 | 1995 | 45 | 0.150 |
Why?
|
| Receptors, LDL | 1 | 2019 | 105 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 564 | 0.150 |
Why?
|
| Proteins | 4 | 2021 | 1038 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 253 | 0.140 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 6 | 0.140 |
Why?
|
| Epitopes | 5 | 1994 | 436 | 0.140 |
Why?
|
| Acridines | 1 | 1998 | 7 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 159 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 1998 | 1829 | 0.140 |
Why?
|
| Curriculum | 1 | 2003 | 765 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 146 | 0.140 |
Why?
|
| Smell | 1 | 2019 | 131 | 0.140 |
Why?
|
| Deafness | 1 | 1998 | 85 | 0.140 |
Why?
|
| Blindness | 1 | 1998 | 76 | 0.140 |
Why?
|
| ran GTP-Binding Protein | 1 | 2017 | 29 | 0.140 |
Why?
|
| Prevalence | 6 | 2025 | 2659 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 917 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 5 | 2013 | 1803 | 0.130 |
Why?
|
| Receptors, Dopamine | 2 | 2013 | 32 | 0.130 |
Why?
|
| Cell Nucleus | 3 | 2016 | 595 | 0.130 |
Why?
|
| Rats | 10 | 2011 | 3612 | 0.130 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 81 | 0.130 |
Why?
|
| RNA, Antisense | 1 | 2017 | 36 | 0.130 |
Why?
|
| Frontotemporal Dementia | 1 | 2018 | 73 | 0.130 |
Why?
|
| Calcium Channels | 3 | 2007 | 163 | 0.130 |
Why?
|
| Polysomnography | 1 | 2018 | 155 | 0.130 |
Why?
|
| Protein Binding | 5 | 2019 | 1735 | 0.130 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1996 | 9 | 0.130 |
Why?
|
| China | 4 | 2021 | 290 | 0.130 |
Why?
|
| Child | 24 | 2014 | 25758 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 775 | 0.130 |
Why?
|
| Neck Muscles | 1 | 1996 | 13 | 0.130 |
Why?
|
| Ceruletide | 1 | 1996 | 2 | 0.130 |
Why?
|
| Solvents | 1 | 1996 | 46 | 0.130 |
Why?
|
| Fluphenazine | 1 | 1996 | 5 | 0.130 |
Why?
|
| Genetic Association Studies | 4 | 2013 | 856 | 0.130 |
Why?
|
| Sensorimotor Cortex | 1 | 2016 | 7 | 0.130 |
Why?
|
| Mitomycins | 2 | 1995 | 9 | 0.130 |
Why?
|
| Latin America | 2 | 2013 | 99 | 0.120 |
Why?
|
| Dopamine Antagonists | 1 | 1996 | 39 | 0.120 |
Why?
|
| Adenylyl Cyclases | 1 | 1996 | 67 | 0.120 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 161 | 0.120 |
Why?
|
| Retina | 2 | 2017 | 492 | 0.120 |
Why?
|
| Channelopathies | 1 | 2016 | 13 | 0.120 |
Why?
|
| Corpus Striatum | 1 | 1996 | 96 | 0.120 |
Why?
|
| Neurologic Examination | 7 | 2012 | 202 | 0.120 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 14 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 197 | 0.120 |
Why?
|
| DNA Damage | 3 | 2015 | 513 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2019 | 530 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 115 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 549 | 0.120 |
Why?
|
| Pyrazoles | 1 | 1998 | 330 | 0.120 |
Why?
|
| Leukocytes | 4 | 2004 | 209 | 0.120 |
Why?
|
| Affect | 2 | 2012 | 173 | 0.120 |
Why?
|
| Protein Kinase C-delta | 2 | 2015 | 16 | 0.110 |
Why?
|
| Ocular Motility Disorders | 1 | 2015 | 38 | 0.110 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 584 | 0.110 |
Why?
|
| Muscle, Skeletal | 3 | 2018 | 1038 | 0.110 |
Why?
|
| Italy | 3 | 2014 | 130 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 2 | 2017 | 573 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 19 | 6 | 1996 | 65 | 0.110 |
Why?
|
| Blotting, Southern | 5 | 2006 | 214 | 0.110 |
Why?
|
| Hot Temperature | 2 | 1985 | 142 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2012 | 55 | 0.110 |
Why?
|
| Atrophy | 2 | 2013 | 252 | 0.110 |
Why?
|
| Sound Localization | 1 | 2013 | 1 | 0.110 |
Why?
|
| Genetics, Population | 4 | 2013 | 188 | 0.100 |
Why?
|
| Histidine | 1 | 2013 | 77 | 0.100 |
Why?
|
| Antibodies | 3 | 1994 | 367 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 3698 | 0.100 |
Why?
|
| Indians, North American | 1 | 2013 | 68 | 0.100 |
Why?
|
| Behavior, Animal | 1 | 1996 | 506 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2003 | 1252 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 1985 | 169 | 0.100 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1158 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2013 | 42 | 0.100 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 45 | 0.100 |
Why?
|
| Protein Conformation | 2 | 1994 | 825 | 0.100 |
Why?
|
| Receptors, Kainic Acid | 1 | 2012 | 6 | 0.100 |
Why?
|
| Genomics | 1 | 2021 | 1651 | 0.100 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 62 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2015 | 611 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2013 | 98 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 589 | 0.090 |
Why?
|
| Olfactory Perception | 1 | 2012 | 32 | 0.090 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 149 | 0.090 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 120 | 0.090 |
Why?
|
| Diseases in Twins | 1 | 1992 | 97 | 0.090 |
Why?
|
| Twins, Monozygotic | 1 | 1992 | 127 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 1994 | 328 | 0.090 |
Why?
|
| alpha-Synuclein | 2 | 2006 | 134 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2012 | 111 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 1996 | 491 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2011 | 1597 | 0.090 |
Why?
|
| Alcoholic Beverages | 1 | 2011 | 18 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1130 | 0.090 |
Why?
|
| Argentina | 2 | 2011 | 52 | 0.090 |
Why?
|
| Cell Survival | 3 | 2017 | 869 | 0.090 |
Why?
|
| Linkage Disequilibrium | 2 | 2003 | 317 | 0.090 |
Why?
|
| Monitoring, Ambulatory | 1 | 2011 | 56 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 183 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 210 | 0.090 |
Why?
|
| Arginine | 1 | 2013 | 341 | 0.090 |
Why?
|
| Cellular Reprogramming | 1 | 2012 | 130 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 1253 | 0.090 |
Why?
|
| Vision Disorders | 1 | 2013 | 217 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2002 | 84 | 0.090 |
Why?
|
| Home Care Services | 1 | 2011 | 73 | 0.090 |
Why?
|
| Mitochondria | 3 | 2014 | 752 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 3021 | 0.090 |
Why?
|
| Family | 1 | 2014 | 594 | 0.090 |
Why?
|
| Multiple Sclerosis | 2 | 1985 | 382 | 0.080 |
Why?
|
| TATA-Box Binding Protein | 2 | 2007 | 31 | 0.080 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2010 | 7 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 176 | 0.080 |
Why?
|
| Serine | 1 | 2011 | 166 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2020 | 771 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 1998 | 1047 | 0.080 |
Why?
|
| Glycine | 1 | 2011 | 162 | 0.080 |
Why?
|
| Cataract | 1 | 1992 | 169 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 7 | 2002 | 4764 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2013 | 387 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 946 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 551 | 0.080 |
Why?
|
| Electroencephalography | 5 | 2021 | 908 | 0.080 |
Why?
|
| Synucleins | 2 | 2000 | 15 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17374 | 0.080 |
Why?
|
| Parents | 2 | 1994 | 1080 | 0.080 |
Why?
|
| Gene Editing | 2 | 2024 | 212 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 359 | 0.070 |
Why?
|
| United States | 6 | 2015 | 11627 | 0.070 |
Why?
|
| Complement System Proteins | 2 | 1985 | 59 | 0.070 |
Why?
|
| Liver Neoplasms | 5 | 2000 | 1396 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 5 | 2000 | 1052 | 0.070 |
Why?
|
| Exome | 1 | 2013 | 1086 | 0.070 |
Why?
|
| COS Cells | 2 | 2006 | 269 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2012 | 2494 | 0.070 |
Why?
|
| Skin Absorption | 1 | 1987 | 7 | 0.070 |
Why?
|
| Psychological Tests | 3 | 2001 | 94 | 0.070 |
Why?
|
| Flurbiprofen | 1 | 1987 | 6 | 0.070 |
Why?
|
| Skin Temperature | 1 | 1987 | 17 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1995 | 140 | 0.070 |
Why?
|
| Penetrance | 3 | 2021 | 113 | 0.070 |
Why?
|
| HeLa Cells | 3 | 2018 | 732 | 0.070 |
Why?
|
| Propionates | 1 | 1987 | 33 | 0.070 |
Why?
|
| Self Medication | 1 | 2007 | 21 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2004 | 368 | 0.070 |
Why?
|
| Receptors, Dopamine D4 | 2 | 2013 | 6 | 0.070 |
Why?
|
| Apoptosis | 2 | 2015 | 1904 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2512 | 0.070 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2013 | 33 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2013 | 29 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4694 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2003 | 1966 | 0.070 |
Why?
|
| Sarcoma 180 | 2 | 1998 | 2 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2007 | 54 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2018 | 1292 | 0.070 |
Why?
|
| Neuromuscular Junction | 2 | 1985 | 92 | 0.070 |
Why?
|
| Genetic Carrier Screening | 2 | 2004 | 72 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2007 | 63 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2018 | 413 | 0.070 |
Why?
|
| Muscle Spasticity | 2 | 2013 | 61 | 0.060 |
Why?
|
| Hemiplegia | 1 | 1986 | 43 | 0.060 |
Why?
|
| Gait Ataxia | 1 | 2006 | 5 | 0.060 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2006 | 9 | 0.060 |
Why?
|
| Genes, Plant | 1 | 2006 | 40 | 0.060 |
Why?
|
| Plant Diseases | 1 | 2006 | 26 | 0.060 |
Why?
|
| PC12 Cells | 1 | 2006 | 28 | 0.060 |
Why?
|
| Heterozygote | 2 | 2020 | 716 | 0.060 |
Why?
|
| Child, Preschool | 11 | 2013 | 14718 | 0.060 |
Why?
|
| Oryza | 1 | 2006 | 29 | 0.060 |
Why?
|
| Nerve Growth Factor | 1 | 2006 | 25 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 406 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 383 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2011 | 150 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 142 | 0.060 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 36 | 0.060 |
Why?
|
| Evoked Potentials, Visual | 1 | 1985 | 34 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13017 | 0.060 |
Why?
|
| ras Proteins | 1 | 2006 | 146 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 166 | 0.060 |
Why?
|
| Carbachol | 2 | 1982 | 15 | 0.060 |
Why?
|
| Motor Endplate | 1 | 1985 | 7 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 333 | 0.060 |
Why?
|
| Carbamazepine | 2 | 2021 | 47 | 0.060 |
Why?
|
| T-Lymphocytes | 5 | 2002 | 1758 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 4725 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 3982 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 309 | 0.060 |
Why?
|
| Mosaicism | 2 | 1997 | 250 | 0.050 |
Why?
|
| Electromyography | 2 | 2013 | 140 | 0.050 |
Why?
|
| Minocycline | 1 | 2004 | 42 | 0.050 |
Why?
|
| Age Factors | 5 | 2007 | 2922 | 0.050 |
Why?
|
| Glycogen Phosphorylase, Muscle Form | 1 | 2003 | 1 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 49 | 0.050 |
Why?
|
| Immersion | 1 | 1983 | 8 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 1983 | 7 | 0.050 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2003 | 2 | 0.050 |
Why?
|
| Acanthocytes | 1 | 2003 | 1 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1653 | 0.050 |
Why?
|
| Brain Stem | 2 | 2020 | 118 | 0.050 |
Why?
|
| Specialty Boards | 1 | 2003 | 25 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2020 | 342 | 0.050 |
Why?
|
| Quantitative Trait Loci | 3 | 2013 | 313 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 1046 | 0.050 |
Why?
|
| History, 20th Century | 3 | 2015 | 387 | 0.050 |
Why?
|
| Homozygote | 2 | 2002 | 549 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 1986 | 484 | 0.050 |
Why?
|
| Accreditation | 1 | 2003 | 94 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 86 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 989 | 0.050 |
Why?
|
| Time Factors | 4 | 2013 | 6445 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2023 | 42 | 0.050 |
Why?
|
| Ataxin-7 | 2 | 1999 | 14 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 433 | 0.050 |
Why?
|
| Neural Pathways | 2 | 2016 | 281 | 0.050 |
Why?
|
| DNA, Superhelical | 1 | 2003 | 22 | 0.050 |
Why?
|
| Germ Cells | 1 | 2004 | 204 | 0.050 |
Why?
|
| Executive Function | 1 | 2024 | 127 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 121 | 0.050 |
Why?
|
| Cognition Disorders | 2 | 2024 | 571 | 0.050 |
Why?
|
| Epilepsy, Complex Partial | 1 | 2002 | 14 | 0.050 |
Why?
|
| Base Composition | 2 | 2018 | 74 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2022 | 297 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 150 | 0.050 |
Why?
|
| Spasms, Infantile | 2 | 2004 | 175 | 0.050 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2002 | 62 | 0.050 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2002 | 6 | 0.050 |
Why?
|
| Torpedo | 4 | 2002 | 35 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 67 | 0.050 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 241 | 0.050 |
Why?
|
| Syndrome | 3 | 1998 | 1173 | 0.050 |
Why?
|
| Doxorubicin | 3 | 2004 | 303 | 0.050 |
Why?
|
| Spain | 1 | 2002 | 65 | 0.050 |
Why?
|
| Myocytes, Cardiac | 2 | 2018 | 652 | 0.050 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2001 | 13 | 0.050 |
Why?
|
| Anticonvulsants | 2 | 2021 | 390 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 70 | 0.050 |
Why?
|
| Eye Abnormalities | 2 | 2013 | 104 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2021 | 10 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 459 | 0.050 |
Why?
|
| Antibody Formation | 4 | 2002 | 274 | 0.040 |
Why?
|
| Cell Division | 2 | 2001 | 744 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 1987 | 219 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 86 | 0.040 |
Why?
|
| Canada | 1 | 2002 | 341 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 311 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 89 | 0.040 |
Why?
|
| RNA, Transfer, Glu | 1 | 2000 | 2 | 0.040 |
Why?
|
| Cyclins | 1 | 2001 | 100 | 0.040 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2000 | 9 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2000 | 13 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 109 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2000 | 62 | 0.040 |
Why?
|
| Epileptic Syndromes | 1 | 2021 | 32 | 0.040 |
Why?
|
| Synaptic Transmission | 3 | 2012 | 332 | 0.040 |
Why?
|
| Cuba | 1 | 2020 | 7 | 0.040 |
Why?
|
| Mandibular Diseases | 1 | 1980 | 10 | 0.040 |
Why?
|
| Facial Muscles | 1 | 1980 | 25 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 20 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 841 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2013 | 8538 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 34 | 0.040 |
Why?
|
| Poly A | 2 | 2016 | 45 | 0.040 |
Why?
|
| Biostatistics | 1 | 2020 | 14 | 0.040 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2003 | 305 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2000 | 117 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2000 | 24 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 200 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2000 | 26 | 0.040 |
Why?
|
| Polyadenylation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Eyelid Diseases | 1 | 1980 | 55 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 142 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 72 | 0.040 |
Why?
|
| Blepharospasm | 1 | 1980 | 44 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 704 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2001 | 618 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 130 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 201 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 591 | 0.040 |
Why?
|
| Carcinoma, Giant Cell | 1 | 1999 | 2 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1986 | 2171 | 0.040 |
Why?
|
| Protons | 1 | 1999 | 98 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2002 | 686 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 44 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2011 | 1118 | 0.040 |
Why?
|
| Greece | 1 | 1998 | 11 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 170 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 141 | 0.040 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2019 | 82 | 0.040 |
Why?
|
| RNA 3' Polyadenylation Signals | 1 | 2018 | 1 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 399 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1176 | 0.040 |
Why?
|
| Walking | 2 | 2011 | 232 | 0.040 |
Why?
|
| Ion Channels | 2 | 2014 | 206 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 1995 | 56 | 0.040 |
Why?
|
| Liver Diseases | 1 | 1982 | 386 | 0.040 |
Why?
|
| Mice, Nude | 2 | 1998 | 757 | 0.040 |
Why?
|
| Patient Selection | 2 | 2016 | 732 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 151 | 0.040 |
Why?
|
| Chromosome Segregation | 2 | 2011 | 73 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2008 | 70 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 1998 | 26 | 0.040 |
Why?
|
| Software | 1 | 2023 | 729 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2142 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 54 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 47 | 0.040 |
Why?
|
| Nurses | 1 | 1998 | 74 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 140 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 1983 | 991 | 0.030 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 42 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 124 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 691 | 0.030 |
Why?
|
| Restless Legs Syndrome | 1 | 2017 | 17 | 0.030 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1998 | 47 | 0.030 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2017 | 17 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 194 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 273 | 0.030 |
Why?
|
| Exons | 2 | 2013 | 802 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1998 | 322 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 87 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2000 | 332 | 0.030 |
Why?
|
| Cloning, Molecular | 3 | 2011 | 813 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2015 | 799 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2008 | 127 | 0.030 |
Why?
|
| Spiperone | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 810 | 0.030 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2016 | 3 | 0.030 |
Why?
|
| Disability Evaluation | 2 | 2008 | 194 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2017 | 141 | 0.030 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1996 | 33 | 0.030 |
Why?
|
| Hand Strength | 1 | 2016 | 60 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 347 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 447 | 0.030 |
Why?
|
| Alcoholism | 1 | 1998 | 250 | 0.030 |
Why?
|
| Benzazepines | 1 | 1996 | 48 | 0.030 |
Why?
|
| Leukemia P388 | 1 | 1995 | 2 | 0.030 |
Why?
|
| Cell Membrane | 3 | 1994 | 473 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 1995 | 18 | 0.030 |
Why?
|
| Clone Cells | 1 | 1996 | 179 | 0.030 |
Why?
|
| Biotransformation | 1 | 1995 | 56 | 0.030 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 1998 | 239 | 0.030 |
Why?
|
| Maps as Topic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 1995 | 38 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 1994 | 201 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 293 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 44 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 73 | 0.030 |
Why?
|
| Torticollis | 1 | 1996 | 72 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 285 | 0.030 |
Why?
|
| Arm | 2 | 2005 | 77 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1996 | 245 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2017 | 148 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1996 | 329 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 86 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 309 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2016 | 174 | 0.030 |
Why?
|
| Drosophila | 1 | 2020 | 822 | 0.030 |
Why?
|
| Nigeria | 1 | 1995 | 74 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 135 | 0.030 |
Why?
|
| PubMed | 1 | 2015 | 23 | 0.030 |
Why?
|
| Bolivia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1723 | 0.030 |
Why?
|
| Pregnancy | 3 | 2018 | 7551 | 0.030 |
Why?
|
| Leg | 2 | 2005 | 134 | 0.030 |
Why?
|
| Teratoma | 1 | 2016 | 130 | 0.030 |
Why?
|
| Voice | 1 | 1995 | 17 | 0.030 |
Why?
|
| Dopamine | 1 | 1996 | 253 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 1306 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2015 | 35 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 100 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 361 | 0.030 |
Why?
|
| Immunization | 3 | 1994 | 312 | 0.030 |
Why?
|
| Infant | 6 | 2013 | 13039 | 0.030 |
Why?
|
| Sequence Alignment | 2 | 2011 | 615 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 1998 | 2683 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1994 | 51 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 1038 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 271 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 23 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 406 | 0.030 |
Why?
|
| Drug Stability | 1 | 1993 | 59 | 0.030 |
Why?
|
| Auditory Threshold | 1 | 2013 | 17 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 89 | 0.030 |
Why?
|
| CELF1 Protein | 2 | 2006 | 48 | 0.030 |
Why?
|
| Blood Cells | 1 | 1993 | 56 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 2 | 2004 | 20 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1995 | 260 | 0.030 |
Why?
|
| Mammals | 1 | 2015 | 271 | 0.030 |
Why?
|
| Neuroacanthocytosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1997 | 462 | 0.030 |
Why?
|
| Myopathies, Nemaline | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hearing | 1 | 2013 | 61 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2013 | 10 | 0.030 |
Why?
|
| Gestational Age | 1 | 1997 | 1227 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 43 | 0.030 |
Why?
|
| Fathers | 1 | 1994 | 72 | 0.030 |
Why?
|
| Cues | 1 | 2013 | 101 | 0.030 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2013 | 7 | 0.030 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2013 | 41 | 0.020 |
Why?
|
| Pyridostigmine Bromide | 1 | 1992 | 12 | 0.020 |
Why?
|
| Myocardium | 1 | 2018 | 908 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 99 | 0.020 |
Why?
|
| Optic Atrophy | 1 | 2013 | 48 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 634 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 728 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 1837 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 422 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 432 | 0.020 |
Why?
|
| Facial Expression | 1 | 2012 | 28 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 44 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1348 | 0.020 |
Why?
|
| Enzootic Bovine Leukosis | 1 | 1992 | 1 | 0.020 |
Why?
|
| Prednisone | 1 | 1992 | 252 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 586 | 0.020 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1992 | 16 | 0.020 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1995 | 455 | 0.020 |
Why?
|
| Paralysis | 1 | 1992 | 29 | 0.020 |
Why?
|
| Nucleotides, Cyclic | 2 | 1982 | 7 | 0.020 |
Why?
|
| Carbazoles | 1 | 1992 | 29 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1992 | 254 | 0.020 |
Why?
|
| Hepatic Artery | 2 | 2000 | 47 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 133 | 0.020 |
Why?
|
| Japan | 2 | 2004 | 154 | 0.020 |
Why?
|
| Prognosis | 2 | 2015 | 5008 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 761 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 2 | 2008 | 76 | 0.020 |
Why?
|
| Venezuela | 1 | 2011 | 15 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 25 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1992 | 120 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 372 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1672 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2011 | 33 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 1992 | 68 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 37 | 0.020 |
Why?
|
| Blepharoptosis | 1 | 1992 | 63 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 1992 | 135 | 0.020 |
Why?
|
| Molecular Biology | 2 | 2004 | 73 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1613 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 544 | 0.020 |
Why?
|
| Mothers | 1 | 1994 | 372 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 251 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1995 | 511 | 0.020 |
Why?
|
| Indoles | 1 | 1992 | 201 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 270 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 427 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2006 | 136 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 425 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1982 | 803 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 93 | 0.020 |
Why?
|
| Spectrin | 1 | 2011 | 62 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 698 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 277 | 0.020 |
Why?
|
| Sex Factors | 1 | 1994 | 1349 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2017 | 893 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 365 | 0.020 |
Why?
|
| Speech Disorders | 1 | 2010 | 48 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 283 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 1161 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 241 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2011 | 231 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 370 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1985 | 161 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2013 | 707 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2444 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 573 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1998 | 1578 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 273 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1988 | 48 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1988 | 64 | 0.020 |
Why?
|
| Anxiety | 1 | 1995 | 1002 | 0.020 |
Why?
|
| Neurons | 1 | 2018 | 2016 | 0.020 |
Why?
|
| Costa Rica | 1 | 2008 | 15 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 273 | 0.020 |
Why?
|
| Polychondritis, Relapsing | 1 | 1988 | 5 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 417 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2007 | 24 | 0.020 |
Why?
|
| Genes | 1 | 1988 | 312 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 1541 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1987 | 67 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 98 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2000 | 106 | 0.020 |
Why?
|
| Risk Factors | 2 | 1992 | 10902 | 0.020 |
Why?
|
| Vasculitis | 1 | 1988 | 50 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 982 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1988 | 119 | 0.020 |
Why?
|
| Reflex, Abnormal | 1 | 1986 | 14 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 2306 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2006 | 6 | 0.020 |
Why?
|
| Chromosomes, Plant | 1 | 2006 | 6 | 0.020 |
Why?
|
| Portugal | 1 | 2006 | 9 | 0.020 |
Why?
|
| DNA Primers | 2 | 2000 | 637 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2004 | 448 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 616 | 0.020 |
Why?
|
| Ascomycota | 1 | 2006 | 26 | 0.020 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 18 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 324 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 408 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 1035 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 1589 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2006 | 253 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1986 | 142 | 0.020 |
Why?
|
| Thymus Gland | 2 | 1985 | 100 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 652 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1975 | 33 | 0.020 |
Why?
|
| Muramidase | 2 | 1975 | 89 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1093 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 1985 | 2 | 0.010 |
Why?
|
| Baths | 1 | 1985 | 15 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 470 | 0.010 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1985 | 2 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 1985 | 12 | 0.010 |
Why?
|
| Quinuclidines | 1 | 1985 | 8 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 182 | 0.010 |
Why?
|
| Ethyl Methanesulfonate | 1 | 2004 | 8 | 0.010 |
Why?
|
| Synaptosomes | 1 | 1985 | 31 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2004 | 27 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1985 | 64 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 41 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2004 | 69 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 89 | 0.010 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2005 | 46 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 35 | 0.010 |
Why?
|
| Eye | 1 | 2006 | 236 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1996 | 180 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1830 | 0.010 |
Why?
|
| AT Rich Sequence | 1 | 2004 | 3 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 3873 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 103 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 307 | 0.010 |
Why?
|
| Fluorescence | 1 | 2004 | 103 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 92 | 0.010 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2003 | 1 | 0.010 |
Why?
|
| North America | 1 | 2004 | 265 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1985 | 266 | 0.010 |
Why?
|
| Hodgkin Disease | 2 | 1986 | 305 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 173 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1995 | 309 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 2003 | 24 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 137 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1983 | 145 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2004 | 114 | 0.010 |
Why?
|
| Movement | 1 | 2004 | 169 | 0.010 |
Why?
|
| Dystonic Disorders | 1 | 2004 | 94 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 276 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2006 | 413 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 41 | 0.010 |
Why?
|
| Base Pairing | 1 | 2003 | 41 | 0.010 |
Why?
|
| Phenytoin | 1 | 1983 | 60 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 938 | 0.010 |
Why?
|
| Cosmids | 2 | 1992 | 42 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 510 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2003 | 123 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1294 | 0.010 |
Why?
|
| Thymectomy | 1 | 1982 | 23 | 0.010 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2002 | 33 | 0.010 |
Why?
|
| Bungarotoxins | 1 | 1982 | 14 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1982 | 75 | 0.010 |
Why?
|
| France | 1 | 2002 | 89 | 0.010 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 1982 | 56 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 2003 | 312 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1982 | 204 | 0.010 |
Why?
|
| DNA Replication | 1 | 2003 | 353 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2000 | 39 | 0.010 |
Why?
|
| Fatty Liver | 1 | 1982 | 211 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2003 | 392 | 0.010 |
Why?
|
| Antigens, Fungal | 1 | 2000 | 34 | 0.010 |
Why?
|
| Epirubicin | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cerebellar Cortex | 1 | 2000 | 20 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2000 | 27 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2000 | 39 | 0.010 |
Why?
|
| Lod Score | 1 | 2000 | 128 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 1451 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 139 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 190 | 0.010 |
Why?
|
| Cell Migration Inhibition | 2 | 1975 | 10 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1999 | 37 | 0.010 |
Why?
|
| Keratins | 1 | 1999 | 52 | 0.010 |
Why?
|
| Hospitals, Special | 1 | 1998 | 11 | 0.010 |
Why?
|
| Genes, ras | 1 | 1999 | 100 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1998 | 24 | 0.010 |
Why?
|
| Vimentin | 1 | 1999 | 69 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1992 | 341 | 0.010 |
Why?
|
| Mesoderm | 1 | 1999 | 110 | 0.010 |
Why?
|
| Osteoclasts | 1 | 1999 | 72 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 1255 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1998 | 4 | 0.010 |
Why?
|
| Epithelium | 1 | 1999 | 354 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2000 | 439 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2000 | 324 | 0.010 |
Why?
|
| Cattle | 2 | 1992 | 571 | 0.010 |
Why?
|
| Paternity | 1 | 1996 | 8 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 675 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1999 | 437 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 1017 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1997 | 296 | 0.010 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 1975 | 4 | 0.010 |
Why?
|
| Rabbits | 1 | 1997 | 688 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 1995 | 54 | 0.010 |
Why?
|
| Calcium | 1 | 1981 | 1083 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 1995 | 25 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 78 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1982 | 899 | 0.010 |
Why?
|
| Mitral Valve Prolapse | 1 | 1995 | 37 | 0.010 |
Why?
|
| CHO Cells | 1 | 1995 | 158 | 0.010 |
Why?
|
| Systole | 1 | 1995 | 203 | 0.010 |
Why?
|
| Diastole | 1 | 1995 | 180 | 0.010 |
Why?
|
| Cricetinae | 1 | 1995 | 381 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 1995 | 172 | 0.010 |
Why?
|
| Macrophages | 2 | 1975 | 693 | 0.010 |
Why?
|
| Incidence | 1 | 2002 | 3365 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 1995 | 130 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1992 | 15 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 723 | 0.010 |
Why?
|
| Genomic Library | 1 | 1992 | 40 | 0.010 |
Why?
|
| Chromosomes, Fungal | 1 | 1992 | 49 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 124 | 0.010 |
Why?
|
| Indole Alkaloids | 1 | 1992 | 1 | 0.010 |
Why?
|
| Microvilli | 1 | 1992 | 69 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 1443 | 0.010 |
Why?
|
| Surface Properties | 1 | 1992 | 95 | 0.010 |
Why?
|
| Binding Sites | 1 | 1994 | 1256 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1992 | 111 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 69 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 212 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 311 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 1992 | 120 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1992 | 118 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 219 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 296 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1990 | 108 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1990 | 118 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 1992 | 295 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1990 | 220 | 0.000 |
Why?
|
| Down-Regulation | 1 | 1992 | 679 | 0.000 |
Why?
|
| Egg White | 2 | 1975 | 9 | 0.000 |
Why?
|
| Ascitic Fluid | 2 | 1975 | 31 | 0.000 |
Why?
|
| Chickens | 2 | 1975 | 304 | 0.000 |
Why?
|
| Tissue Extracts | 1 | 1985 | 12 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1985 | 23 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 83 | 0.000 |
Why?
|
| Synaptic Membranes | 1 | 1985 | 23 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 161 | 0.000 |
Why?
|
| Zinc | 1 | 1985 | 125 | 0.000 |
Why?
|
| Ligation | 1 | 1983 | 139 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 5399 | 0.000 |
Why?
|
| Catheterization | 1 | 1983 | 241 | 0.000 |
Why?
|
| Pain Management | 1 | 1983 | 199 | 0.000 |
Why?
|
| Radiography | 1 | 1983 | 818 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1981 | 51 | 0.000 |
Why?
|
| Palliative Care | 1 | 1983 | 457 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1975 | 99 | 0.000 |
Why?
|
| Antigens | 1 | 1975 | 149 | 0.000 |
Why?
|
| Immunologic Memory | 1 | 1975 | 199 | 0.000 |
Why?
|